FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Table of Contents
for Market Access Impact (US) [Myeloma] [Report Updated: 01-09-2017]
1.What are market barriers?
2.About this report
3.About the survey
4.Brands included in the survey
|Title||Date Published||Price from||More Details|
| Market Access Excellence for Emerging Markets|
IntroductionWhat knowledge, strategies, and resources do you need right now to maximise your company...
|01 May 2015 by FirstWord Pharma||USD $1,866 (normally
| Expanded Access Programs: Opportunities and Challenges for Pharma|
IntroductionExpanded access programmes make available investigational drugs to chronically sick or d...
|20 Apr 2015 by FirstWord Pharma||USD $506 (normally
| Orphan Drug Market Access: Payer Insights on the Present and Future|
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
|14 Oct 2014 by FirstWord Pharma||USD $591 (normally
| Market Access Team Management: driving exceptional performance|
IntroductionThe demands on market access teams are growing rapidly as the specific needs of key stak...
|12 Aug 2014 by FirstWord Pharma||USD $591 (normally
| Oncology Market Access Europe – Payer and Industry Perspectives|
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
|03 Jul 2014 by FirstWord Pharma||USD $846 (normally
| Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?|
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
|28 Apr 2014 by FirstWord Pharma||USD $591 (normally
| The Reality of Market Access in Europe: the role of Health Technology Assessment|
IntroductionFaced with slipping or negligible GDP growth and an economic crisis, Eurozone countries ...
|10 Mar 2014 by FirstWord Pharma||USD $591 (normally
| Market Access for Orphan Drugs: assessing the global landscape|
IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
|01 Dec 2013 by FirstWord Pharma||USD $591 (normally
| Market Access in the EU5 – a comparative overview|
IntroductionThe sustained and challenging economic environment in the EU has impacted – and is impac...
|01 Aug 2013 by FirstWord Pharma||USD $336 (normally
| Market Access: Communicating Value Stories to Payers|
IntroductionThroughout the EU, reimbursement decisions are increasingly decentralised, making the pr...
|01 Apr 2012 by FirstWord Pharma||USD $591 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.